Akums Drugs and Pharma has raised Rs.828.78 crore from anchor investors in advance of its public IPO.
Indian pharmaceuticals manufacturer Akums Drugs and Pharmaceuticals Limited has allocated 1.22 crore equity shares at Rs.679 per share to anchor investors, according to an exchange filing. Through this anchor round, the company raised Rs.828.78 crore.
According to a filing on the Bombay Stock Exchange (BSE), Akums Drugs and Pharmaceuticals Limited announced that it raised nearly Rs.828.78 crore from anchor investors ahead of its initial public offering on Tuesday, July 30. The pharmaceutical manufacturing company allocated 1.22 crore equity shares at Rs.679 per share to its anchor investors on Monday, July 29.
Among the top anchor allocations for the share issue in the anchor round on Monday were SBI Healthcare Opportunities Fund, SBI Conservative Hybrid Fund, International Growth and Income Fund, Smallcap World Fund, Abu Dhabi Investment Authority, DSP India Fund, IIFL Asset Management Limited, BlackRock Emerging Frontiers Master Fund Limited, and BlackRock Global Funds - India Fund.
According to the filing, out of the total 1.22 crore equity shares allocated to anchor investors, 41,75,208 shares (41.75 lakh), or 34.21 percent, were allotted to domestic mutual funds that applied through 24 schemes.
SBI Healthcare Opportunities Fund and SBI Conservative Hybrid Fund received the largest equity share allocations, at 7.84 percent and 11.09 percent, respectively.
The book runners for the public issue are ICICI Securities Limited, Axis Capital Limited, Citigroup Global Market India Private Limited, and Ambit Private Limited.
Details of Akums Drugs and Pharmaceuticals IPO:
The pharmaceutical company will open for public subscription on Tuesday, July 30, and close on Thursday, August 1. The price band for the public issue has been set at Rs.646 to Rs.679 per equity share, with a face value of Rs.2 per share.
The company has set the lot size at 22 equity shares and multiples thereof. The funds raised from the public issue will be used to settle the debts of Akums Drugs and its subsidiaries. Additionally, the company plans to allocate funds towards working capital requirements and growth initiatives. Akums Drugs and Pharmaceuticals Limited is expected to list on the exchanges on August 6.
Posted on : 30-07-2024